Phase II trial of induction chemotherapy with carboplatin and paclitaxel plus bevacizumab in patients with stage IIIA to IV nonsquamous non-small cell lung cancer
| Autor: | Masaaki Sano, Satoru Motoyama, Hajime Saito, Kazuhiro Sato, Yoshihiro Minamiya, Taku Nakagawa, Hiroyuki Shibata, Kimito Orino, Ikuo Matsuzaki, Kyoko Nomura, Katsutoshi Nakayama, Kazuhiro Imai, Yusuke Sato |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms Paclitaxel Bevacizumab medicine.medical_treatment Phases of clinical research Carboplatin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Surgical oncology Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Combined Modality Therapy Lung cancer Aged Neoplasm Staging Chemotherapy business.industry Induction chemotherapy Induction Chemotherapy General Medicine Middle Aged medicine.disease Survival Rate Treatment Outcome chemistry 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Surgery business medicine.drug |
| Zdroj: | Surgery Today. 49:678-685 |
| ISSN: | 1436-2813 0941-1291 |
| Popis: | Surgery remains the best curative treatment option for non-small cell lung cancer (NSCLC), but is of benefit only to patients with localized disease. A meta-analysis showed a significant beneficial effect of induction chemotherapy on survival, but there is still no clear evidence. This phase II study was conducted to establish whether induction chemotherapy with carboplatin (CBDCA) and paclitaxel (PTX) plus bevacizumab prior to surgery reduces the risk of progression. The subjects of this study were 29 patients with treatment-naive nonsquamous NSCLC (clinical stages IIIA to IV). Patients received PTX (200 mg/m2), CBDCA (area under the curve, 5), and bevacizumab (15 mg/kg) followed by surgery. Chemotherapy was repeated every 3 weeks for up to six cycles. The overall response rate was 72.4%. Of the 29 patients, ten underwent surgery after the induction chemotherapy and complete resection was achieved in 7 (70%). The median progression-free-survival (PFS) time and the 3-year PFS rate were 0.92 years and 16.2%, respectively. The median overall survival (OS) time and the 3-year OS rate were 1.96 years and 44.9%, respectively. Combined modality therapy with surgery after induction chemotherapy with CBDCA and PTX plus bevacizumab is clinically feasible and tolerable for patients with unknown or negative molecular profiles. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink